Stereotactic Radiosurgery for Brain Cancer
(NASRS Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have had cytotoxic chemotherapy within 7 days before the treatment. Other medications, like targeted therapies, may be allowed at the discretion of your doctor.
What data supports the effectiveness of the treatment Neoadjuvant Stereotactic Radiosurgery for brain cancer?
Research shows that stereotactic radiosurgery, when used after surgery for brain metastases (cancer spread to the brain), can reduce the risk of cancer coming back and improve quality of life compared to whole-brain radiotherapy. This suggests that stereotactic radiosurgery can be an effective treatment option for brain cancer.12345
Is stereotactic radiosurgery generally safe for treating brain conditions?
Stereotactic radiosurgery (SRS) is generally considered safe for treating brain conditions, though there is a low risk of adverse radiation effects (AREs), which can sometimes be confused with tumor progression. Long-term safety concerns include a potential risk of developing secondary brain tumors, but this risk is not well-defined. SRS combined with other treatments like chemotherapy appears to be safe without significant additional side effects.678910
How is neoadjuvant stereotactic radiosurgery different from other treatments for brain cancer?
What is the purpose of this trial?
This study will be a non-randomized phase II trial for patients with one to six brain metastases, at least one of which is appropriate for surgical resection. Upon registration, patients will be assigned to receive neo-adjuvant stereotactic radiosurgery (NASRS).
Research Team
David Shultz, MD
Principal Investigator
University Health Network, Toronto
Eligibility Criteria
This trial is for patients with 1-6 brain metastases, where at least one tumor is large enough to consider surgery but hasn't been operated on yet. Participants must be able to undergo stereotactic radiosurgery (SRS), have a good performance status (ECOG ≤2), and not be pregnant or have certain conditions like widespread cancer in the spinal fluid or previous treatments that would exclude them.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive neoadjuvant stereotactic radiosurgery (NASRS) for brain metastases
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for survival and long-term outcomes
Treatment Details
Interventions
- Neoadjuvant Stereotactic Radiosurgery
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor